Oral anticoagulation is obligatory in patients with atrial fibrillation (AF) to prevent
thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety …

The evidence of direct oral anticoagulants (DOACs) usage for venous thromboembolism
(VTE) in patients at extremes of body weight or mass index is limited. In such situations …

Purpose To investigate real-world prescribing trends and clinical outcomes based on body
mass index (BMI) categorization in patients who received rivaroxaban therapy. Methods This …

Cardiovascular disease (CVD) remains the leading cause of death in the USA. Several risk
factors have been identified, and obesity has become one of prominent concern. Excessive …

Obesity is a significant cause of morbidity and mortality, and it is becoming increasingly
prevalent worldwide. Altered pharmacodynamics and pharmacokinetics of drugs in obese …

Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …

Between 1985 and 2011, the prevalence of obesity, defined as body mass index (BMI) of 30
kg/m2 or higher, increased from 6.1% to 18.3% in Canada. 1 It is estimated that by 2019 …

Essentials• The association of body weight and patient‐important outcomes remains
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …

Abstract Background The International Society on Thrombosis and Haemostasis
recommends avoiding the use of direct oral anticoagulants (DOACs) in patients with a body …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …